BioCentury | Feb 13, 2012
Company News

Cipher, Galephar Pharmaceutical Research Inc., Kowa deal

...million milestone from Kowa after the pharma achieved a cumulative sales milestone for Lipofen ( CIP-fenofibrate...
...through its 2008 acquisition of ProEthic Pharmaceuticals Inc. , which had exclusive rights to market Lipofen...
BioCentury | May 9, 2011
Clinical News

Antara fenofibrate regulatory update

...include lipid lowering drugs Antara fenofibrate from GlaxoSmithKline and Oscient; Fenoglide fenofibrate from LifeCycle Pharma; Lipofen...
...Nagoya, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Products: Antara fenofibrate, Fenoglide fenofibrate, Lipofen ( CIP-fenofibrate...
BioCentury | Jul 12, 2010
Company News

Cipher, Kowa sales and marketing update

...million milestone from Kowa after the pharma achieved a cumulative sales milestone for Lipofen ( CIP-fenofibrate...
...through its 2008 acquisition of ProEthic Pharmaceuticals Inc. , which had exclusive rights to market Lipofen...
BioCentury | Aug 11, 2008
Company News

ProEthic, Kowa deal

...will be transferred to Kowa’s Kowa Research Institute in Morrisville, N.C. ProEthic markets Lipofen ( CIP-fenofibrate...
BioCentury | Feb 7, 2008
Targets & Mechanisms

PPAR-alpha's in cancer

...of cancer, it would significantly increase the size of the fenofibrate market. Cipher's Lipofen ( CIP-fenofibrate...
...millions of dollars to get the necessary data. By contrast, Cipher was able to get Lipofen...
...uses SkyePharma's solubilization IDD-P technology Hypercholesterolemia; hypertriglyceridemia Marketed Cipher Pharmaceuticals Inc. (TSX:DND)/ProEthic Pharmaceuticals Inc. Lipofen (CIP-fenofibrate...
BioCentury | Oct 8, 2007
Company News

ProEthic sales and marketing update

...ProEthic launched Lipofen ( CIP-fenofibrate ) in the U.S. to treat hyperlipidemia. ProEthic has exclusive rights...
BioCentury | Jul 16, 2007
Company News

Cipher, ProEthic sales and marketing update

...ProEthic received exclusive rights to market DND's Lipofen ( CIP-fenofibrate ) in the U.S. to treat...
BioCentury | Feb 27, 2006
Clinical News

CIP-Fenofibrate regulatory update

...DND received marketing approval in Canada for CIP-Fenofibrate to treat hyperlipidemia. The gelatine capsule containing fenofibrate...
...last month (see BioCentury, Jan. 16). Cipher Pharmaceuticals Inc. (TSX:DND), Mississauga, Ontario Product: CIP-Fenofibrate ( Lipofen...
BioCentury | Jan 16, 2006
Clinical News

Lipofen fenofibrate capsules regulatory update

...FDA approved an NDA for 50, 100 and 150 mg Lipofen gelatine capsules containing fenofibrate as...
...or mixed dyslipidemia and to treat hypertriglyceridemia. Cipher Pharmaceuticals Inc. (TSX:DND), Mississauga, Ontario Product: Lipofen fenofibrate capsules...
Items per page:
1 - 9 of 9